Gilead’s remdesivir reduces coronavirus mortality risk: Study
Family emergency medicine physician Dr. Janette Nesheiwat applauds President Trump for securing 100 percent of remdesivir for the month of July and 90 percent for August and September since there’s now a shortage of the drug.
Gilead Sciences Inc said on Monday it has filed a marketing application with the U.S. Food and Drug Administration for its experimental COVID-19 drug remdesivir.
Continue Reading Below
The antiviral drug, to be available under the brand name Veklury, is one of the few treatments to have shown to be effective against the respiratory illness.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The treatment has got the U.S. health regulator’s approval for emergency use in hospitalized patients with severe COVID-19.
The marketing application is supported by data from two late-stage human trials conducted by Gilead and another late-stage trial by the National Institute of Allergy and Infectious Diseases, the company said.
CLICK HERE TO READ MORE ON FOX BUSINESS
The drug has been at the forefront in the fight against the respiratory illness after the intravenously administered medicine helped shorten hospital recovery times in a U.S. trial.
Remdesivir has been approved by multiple regulatory authorities around the world, including in the European Union and Japan.
Source: Read Full Article